Established by seasoned biopharmaceutical veterans, VLP Therapeutics, LLC (VLP) is structured around development of an innovative medical treatment designed to transform traditional vaccine and targeted antibody therapies to address global unmet medical needs. Management's expressed objective is to combat the 21st century global public health problems through application of next generation i-αVLP Technology. VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, auto-immune diseases and neurological diseases. rThe effort is to ceate next-generation virus-like particles that transform traditional vaccine therapies. VLP Therapeutics modifies viruses to create novel cancer and infectious disease vaccine candidates, and the Company's virus-like particle vaccines have proven to be highly immunogenic in multiple animal models. VLP Therapeutics anticipates initiating a human trial of its Malaria vaccine in early 2019.
